AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12866653
Drug: Lactate-buffered CVVH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate-buffered CVVH (treatment A)
Trial: 12866653
Drug: Bicarbonate-buffered CVVH
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicarbonate-buffered CVVH (treatment B)
Trial: 26862930
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with esomeprazole (20 mg), amoxicillin (1000 mg), and clarithromycin (500 mg) twice daily for 7 days
Trial: 26862930
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with 5 days of esomeprazole (20 mg) and amoxicillin (1000 mg) twice daily, followed by 5 days of esomeprazole (20 mg), clarithromycin (500 mg) and metronidazole (400 mg) twice daily
Trial: 26862930
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy with esomeprazole (20 mg), amoxicillin (1000 mg), clarithromycin (500 mg) and metronidazole (400 mg) twice daily for 7 days
Trial: 18251659
Drug: Standard-of-care antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care antimicrobial therapy after surgical incision and drainage
Trial: 16482080
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (1 g per day for 7 days)
Trial: 11038990
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment applied to points: Touwei (ST 8), Xuanlu (GB 5), Fengchi (GB 20), Dazhui (GV 14), Lieque (LU 7), treated with the reducing method.
Trial: 11038990
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug therapy (CDTG)
Trial: 1577051
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose omeprazole (20 mg)
Trial: 1577051
Drug: Short-term omeprazole
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term omeprazole treatment (20 mg/day for 8 days)
Trial: 24627569
Drug: Atenolol treatment
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol treatment for 9 weeks
Trial: 20823377
Drug: Theobromine-enriched cocoa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theobromine-enriched cocoa (979 mg of theobromine)
Trial: 20823377
Drug: Natural dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural dose theobromine cocoa (106 mg of theobromine)
Trial: 11522234
Drug: CD56(+) cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD56(+) cell expandability after CT2 and G-CSF application
Trial: 9590461
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg compressed tablet (CT)
Trial: 9590461
Drug: 3.0 mg
RxNorm normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg sustained release (SR) tablet
Trial: 3197978
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet with one dose of 90 g corn oil after the last meal (120 g fat/day)
Trial: 3197978
Drug: Basal low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal low fat diet containing 30 g of fat per day
Trial: 3197978
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet with doses of 30 g corn oil taken with each of the three meals (120 g fat/day)
Trial: 30642738
Drug: Oral citrulline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral citrulline supplementation (0.18 g/kg/day)
Trial: 22525372
Drug: Houttuyninum (5.52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Houttuyninum (5.52 μg/ml IC50)
Trial: 22525372
Drug: Houttuyninum (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Houttuyninum (in vivo administration)
Trial: 22525372
Drug: Houttuyninum (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Houttuyninum (40 μg/ml)
Trial: 19460169
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy directed to the talocrural joint
Trial: 17529847
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg/d orally)
Trial: 7624915
Drug: N‐SIM (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐SIM (300 mg single dose)
Trial: 2190516
Drug: Erythromycin, 500
RxNorm normalized name: Erythromycin, 500 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin, 500 mg, four times daily for 3 weeks
Trial: 38695
Drug: Pancuronium 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.01 mg/kg
Trial: 38695
Drug: Pancuronium 0.010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.010 to 0.020 mg/kg
Trial: 25926146
Drug: Annual initial
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual initial in-hospital treatment cost for all AUGIB cases in the UK
Trial: 21407248
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements (ONS) for 3 months and dietary counselling at discharge
Trial: 17353582
Drug: Neptune Krill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neptune Krill Oil (NKO) 300 mg daily
Trial: 11951578
Drug: Neuramide (N)
RxNorm normalized name: lauramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuramide (N) administered intramuscularly twice daily for 28 days
Trial: 3377230
Drug: Maximal warming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal warming (warm room, humidified respiratory gases, and warm intravenous fluids)
Trial: 31167512
Drug: Bergamot polyphenol
RxNorm normalized name: BERGAMOT
DrugBank: Bergamot oil (DB14335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bergamot polyphenol extract complex (BPE‐C) 650 mg daily
Trial: 31167512
Drug: Bergamot polyphenol
RxNorm normalized name: BERGAMOT
DrugBank: Bergamot oil (DB14335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bergamot polyphenol extract complex (BPE‐C) 1300 mg daily
Trial: 27846629
Drug: Drug-Eluting Balloon
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Eluting Balloon (DEB) after Cutting Balloon (CB) dilation
Trial: 27846629
Drug: Drug-Eluting Stent
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Eluting Stent (DES) implantation alone
Trial: 25791668
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (IT) - medical therapy plus psychotherapy (8 group and 2 individual sessions)
Trial: 25791668
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (CT) - medical therapy alone
Trial: 25791668
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (IT) - medical therapy plus psychotherapy
Trial: 23571784
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch 6% (2 × 250 ml for 3 days postoperatively)
Trial: 23571784
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution 0.9% (control group)
Trial: 23571784
Drug: Hydroxyethyl starch
RxNorm normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethyl starch 6% and Saline solution 0.9%
Trial: 21963127
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment (15, 30 or 60μg/kg daily)
Trial: 19819787
Drug: Metoprolol 50
RxNorm normalized name: metoprolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 50 mg daily
Trial: 7719087
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (laparoscopy + TCM including low dose Methotrexate, modified Huo‐Luo‐Xiao‐Ling Dan, Ding‐Tong paste, Zi‐Gong pill)
Trial: 31056272
Drug: SFC method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SFC method applied to clinical samples after single intravenous (100 mg), single oral (100 mg), and repeated oral administration (400 mg)
Trial: 16762702
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg preoperatively, 200 mg postoperatively)
Trial: 15328782
Drug: Caffeine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (400 mg at 21:30, followed by 100 mg at 03:00 and 05:00)
Trial: 10718163
Drug: Lamotrigine 125
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine 125 mg
Trial: 10718163
Drug: Lamotrigine 250
RxNorm normalized name: lamotrigine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine 250 mg
Trial: 8883530
Drug: Iodixanol at
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodixanol at 320 mg I/kg
Trial: 1547766
Drug: Intrarectal diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarectal diazepam (DZP) 20 mg
Trial: 1547766
Drug: Intrarectal diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarectal diazepam (DZP) 30 mg
Trial: 2863922
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.5 mg fluphenazine and 10 mg nortriptyline (Motival)
Trial: 2863922
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg fluphenazine
Trial: 2863922
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nortriptyline
Trial: 31593070
Drug: Nasal High
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal High Flow (NHF) therapy
Trial: 23631607
Drug: Acarbose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (50 mg three times a day)
Trial: 21839402
Drug: Ustekinumab (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (45 mg at Weeks 0 and 4)
Trial: 16737665
Drug: Mistletoe lectin
RxNorm normalized name: MISTLETOE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistletoe lectin (ML) derived from IQ
Trial: 16737665
Drug: IQ depleted
RxNorm normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IQ depleted of ML
Trial: 11680559
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy plus group drug counseling
Trial: 11680559
Drug: Supportive-expressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive-expressive therapy plus group drug counseling
Trial: 11680559
Drug: Individual drug
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual drug counseling plus group drug counseling
Trial: 9770877
Drug: Coccinia indica,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coccinia indica, 500 mg/kg body weight, administered orally for six weeks
Trial: 7819650
Drug: Lactobacillus preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus preparation
Trial: 18849052
Drug: 12% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12% sucrose solution (for children aged 6 to 48 months)
Trial: 18849052
Drug: Lidocaine-prilocaine cream
RxNorm normalized name: lidocaine / prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine cream (for children aged 6 to 48 months)
Trial: 15131545
Drug: Atorvastatin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin alone (to reduce LDL cholesterol to < or =80 mg/dL)
Trial: 15131545
Drug: Atorvastatin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin plus antioxidant vitamins C and E (to reduce LDL cholesterol to < or =80 mg/dL)
Trial: 15131545
Drug: Control (diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (diet and low-dose lovastatin to reduce LDL cholesterol to < or =130 mg/dL)
Trial: 9040271
Drug: Combined physical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined physical therapy (twice a week for 60 minutes with a therapist, daily unsupervised exercise for 15 minutes)
Trial: 9040271
Drug: Combined physical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined physical therapy
Trial: 3116238
Drug: Group I
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group I received a nutrient solution providing 10 grams of nitrogen as Perifusin and 1400 calories as dextrose and Intralipid with an osmolality of 490 mosmol/kg
Trial: 30907987
Drug: Levothyroxine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine (50 μg once daily)
Trial: 28077730
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of measles vaccine (MV) at 18 weeks and 9 months
Trial: 28077730
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of measles vaccine (MV) at age 9 months
Trial: 23419384
Drug: Gut-directed hypnotherapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gut-directed hypnotherapy (GHT) with supportive talks and medical treatment (SMT)
Trial: 23419384
Drug: Supportive talks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive talks with medical treatment (SMT)
Trial: 14758818
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (809 nm‐GaAlAs‐laser, 50 mW, 150 s)
Trial: 14758818
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (simulated laser treatment)
Trial: 11355044
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) with conjugated estrogens (0.625 mg/day) and medroxyprogesterone (2.5 mg/day) for 12 months
Trial: 9207871
Drug: Ibuprofen-arginine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen-arginine (400 mg orally, 90 min before surgery, 2 h after surgery, then every 8 h for 32 hours)
Trial: 9207871
Drug: Placebo (doubled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (doubled blind, same timing as ibuprofen-arginine)
Trial: 9207871
Drug: Ibuprofen-arginine and
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen-arginine and Placebo
Trial: 7953427
Drug: 0.2 per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 per cent glyceryl trinitrate ointment
Trial: 3591249
Drug: 1.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/kg of 0.5% bupivacaine injected for the block (Group 1)
Trial: 3591249
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 0.25 mg/kg/h infusion (Group 2)
Trial: 3591249
Drug: 1.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/kg of 0.5% bupivacaine (Group 1)
Trial: 28287913
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill intervention
Trial: 24233772
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple anti‐H. pylori therapy plus probiotics of L. acidophilus and B. bifidum for 2 weeks followed by taking probiotics for another 4 weeks
Trial: 24233772
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple anti‐H. pylori therapy for 6 weeks
Trial: 24233772
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple anti‐H. pylori therapy plus probiotics of L. acidophilus and B. bifidum
Trial: 20339787
Drug: Topical heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical heparin treatment (group TH)
Trial: 17899018
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg morphine
Trial: 16087981
Drug: Valine intake
RxNorm normalized name: Valine
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valine intake of 17 mg x kg(‐1) x d(‐1)
Trial: 16087981
Drug: Valine intakes
RxNorm normalized name: Valine
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valine intakes of 5, 10, 15, 20, 25, 30, and 35 mg x kg(‐1) x d(‐1)
Trial: 16087981
Drug: Leucine intake
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine intake maintained at 40 mg x kg(‐1) x d(‐1)
Trial: 10332195
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of adriamycin (ADM) + vincristine (VCR) + cyclophosphamide (CPM) + mitoxantrone + L-asparaginase
Trial: 10332195
Drug: Attenuated induction
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attenuated induction therapy for patients aged 75 or over
Trial: 10332195
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction therapy for patients aged less than 75
Trial: 8942334
Drug: Edrophonium (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edrophonium (0.75 mg kg‐1)
Trial: 8942334
Drug: Pyridostigmine (0.24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (0.24 mg kg‐1)
Trial: 8942334
Drug: Neostigmine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.05 mg kg‐1)
Trial: 3936186
Drug: Cost-sharing for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-sharing for drugs
Trial: 25222757
Drug: High insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High insulin with essential amino acids (EAAs)
Trial: 25222757
Drug: Low insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low insulin with EAAs
Trial: 25222757
Drug: Low insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low insulin
Trial: 25222757
Drug: High insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High insulin
Trial: 25222757
Drug: EAA infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EAA infusion
Trial: 23229963
Drug: Focus on
RxNorm normalized name: Menthol 2.1 g in 60 mL TOPICAL GEL [Biocool Focus On]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focus on Medicines (FOM) program
Trial: 15857930
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) therapy, administered as three monthly infusions.
Trial: 11490530
Drug: 32P followed
RxNorm normalized name: Sodium phosphate (32P)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 32P followed by low-dose hydroxyurea (HU) maintenance therapy
Trial: 8017870
Drug: 4-aminopyridine (AP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-aminopyridine (AP), oral treatment for 3 months
Trial: 2849011
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Angiotensin II and Vasopressin with CRF41 (100 micrograms)
Trial: 26529074
Drug: Self-administered intradermal
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered intradermal influenza vaccine (Intanza(®))
Trial: 26529074
Drug: Nurse-administered intramuscular
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered intramuscular vaccine (Vaxigrip(®))
Trial: 26529074
Drug: Nurse-led group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led group sessions for self-administration
Trial: 23789889
Drug: Sensor-augmented insulin-pump
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensor-augmented insulin-pump therapy with threshold-suspend feature
Trial: 23789889
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard sensor-augmented insulin-pump therapy)